Trial Information: 51 patients are being recruited for a Phase I/II trial of the XIAP antisense AEG35156 in indolent lymphomas (including follicular lymphoma) and chronic lymphocytic leukemia (CLL). Patients must meet criteria for third-line treatment (or beyond) to enter the trial.
Showing posts with label AEG35156. Show all posts
Showing posts with label AEG35156. Show all posts
Thursday, January 6, 2011
Subscribe to:
Posts (Atom)